Emalex Biosciences
Clinical-stage biotechnology company developing therapies for movement disorders and other neurological conditions, with a focus on Tourette syndrome and tardive dyskinesia.
Website
https://www.emalexbio.com/Location
Waltham, Massachusetts, USA
Founded
2015
Categories
biotech, neurology, movement-disorders, therapeutics, clinical-stage
Notes
Emalex Biosciences is a clinical-stage biotechnology company focused on developing treatments for movement disorders and other neurological conditions. The company was founded to address significant unmet needs in conditions such as Tourette syndrome and tardive dyskinesia.
Emalex is part of the Bain Capital Life Sciences portfolio, which focuses on building companies to address significant unmet medical needs. The company is advancing clinical programs targeting movement disorders that significantly impact patient quality of life.
Team
- Tom McCarthy - CEO
- Leadership team available on company website
Additional Research Findings
- Founded in 2015
- Portfolio company of Bain Capital Life Sciences
- Headquarters in Waltham, Massachusetts
- Focus on movement disorders
- Target indications: Tourette syndrome, tardive dyskinesia
- Clinical-stage programs
- Neurological therapeutics